Early anticoagulation of bioprosthetic aortic valves in older patients: Results from the society of thoracic surgeons adult cardiac surgery national database

Journal of the American College of Cardiology

Volumn 60, Issue 11, 2012, Pages 971-977

  Brennan, J Matthew ^a   Edwards, Fred H ^b   Zhao, Yue ^a   O'Brien, Sean ^a   Booth, Michael E ^a   Dokholyan, Rachel S ^a   Douglas, Pamela S ^a   Peterson, Eric D ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

Author keywords

anticoagulation strategies; aortic valve replacement; outcomes

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGED; ANTICOAGULATION; AORTA VALVE PROSTHESIS; ARTERIAL THROMBOEMBOLISM; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOPERICARDIUM; HEMORRHAGIC SHOCK; HOSPITAL READMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT ASSESSMENT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK; VALVULAR HEART DISEASE;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; AORTIC VALVE; ASPIRIN; BIOPROSTHESIS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEART VALVE PROSTHESIS; HEMORRHAGE; HUMANS; INCIDENCE; MALE; RISK FACTORS; SURVIVAL ANALYSIS; THORACIC SURGERY; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 84865749386     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.05.029     Document Type: Article

References (20)

1. M. Heras, J.H. Chesebro, V. Fuster High risk of thromboemboli early after bioprosthetic cardiac valve replacement J Am Coll Cardiol 25 1995 1111 1119
2. A. Colli, J.P. Verhoye, R. Heijmen ACTION Registry Investigators Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results Eur J Cardiothorac Surg 33 2008 531 536
3. CTSNet Editors, Valve Technology Center Anticoagulation therapy after aortic tissue valve replacement: Final Results. The Cardiothoracic Surgery Network (CTSNet) http://www.ctsnet.org/file/ AnticoagulationSurveyFinalResultsSlidesPDF.pdf Accessed March 16, 2011
4. J.C. Sun, M.J. Davidson, A. Lamy, J.W. Eikelboom Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends Lancet 374 2009 565 576
5. J.I. Aramendi, C.A. Mestres, J. Martinez-Leon, V. Campos, G. Munoz, C. Navas Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial Eur J Cardiothorac Surg 27 2005 854 860
6. A. Colli, C.A. Mestres, M. Castella, T. Gherli Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial J Heart Valve Dis 16 2007 667 671
7. J.I. Aramendi, C.A. Mestres Antithrombotic therapy after bioprosthetic aortic valve replacement Eur J Cardiothorac Surg 33 2008 529 530
8. P. Vaughan, P.D. Waterworth An audit of anticoagulation practice among UK cardiothoracic consultant surgeons following valve replacement/repair J Heart Valve Dis 14 2005 576 582
9. Jacobs JP, Edwards FH, Shahian DM, et al. Successful linking of the Society of Thoracic Surgeons adult cardiac surgery database to Centers for Medicare and Medicaid Services Medicare data. Ann Thorac Surg;90:1150-6; discussion 6-7.
10. R.O. Bonow, B.A. Carabello, K. Chatterjee American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J Am Coll Cardiol 52 2008 e1 e142
11. P. Rosenbaum, D. Rubin The central role of propensity score in observational studies for causal effects Biometrika 70 1983 41 55
12. L.H. Curtis, B.G. Hammill, E.L. Eisenstein, J.M. Kramer, K.J. Anstrom Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases Med Care 45 2007 S103 S107
13. P. Rosenbaum Model-based direct adjustment J Am Stat Assoc 82 1987 387 394
14. S.L. Zeger, K.Y. Liang Longitudinal data analysis for discrete and continuous outcomes Biometrics 42 1986 121 130
15. M. El-Husseiny, K. Salhiyyah, S.G. Raja, J. Dunning Should warfarin be routinely prescribed for the first three months after a bioprosthetic valve replacement? Interact Cardiovasc Thorac Surg 5 2006 616 623
16. F. di Marco, S. Grendene, G. Feltrin, D. Meneghetti, G. Gerosa Antiplatelet therapy in patients receiving aortic bioprostheses: a report of clinical and instrumental safety J Thorac Cardiovasc Surg 133 2007 1597 1603
17. T. Gherli, A. Colli, C. Fragnito Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study Circulation 110 2004 496 500
18. W.R. Jamieson, S.D. Moffatt-Bruce, P. Skarsgard Early antithrombotic therapy for aortic valve bioprostheses: is there an indication for routine use? Ann Thorac Surg 83 2007 549 556 discussion 556-7
19. K. Moinuddeen, J. Quin, R. Shaw Anticoagulation is unnecessary after biological aortic valve replacement Circulation 98 1998 II95 II98 discussion II98-9
20. T.M. Sundt, K.J. Zehr, J.A. Dearani Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg 129 2005 1024 1031